Novocure’s Optune Mya Rejected By FDA Over Uncertainty About Its Clinical Benefit

The company plans to ask whether approval is possible without additional clinical studies; the FDA raised no safety concerns.

Share
Novocure’s Optune Mya Rejected By FDA Over Uncertainty About Its Clinical Benefit

Novocure, which makes wearable devices that deliver electric fields to treat cancer, said Monday that the FDA declined to approve Optune Mya for adults whose lung cancer has spread to the brain. The agency questioned the extent of the treatment’s clinical benefit, rather than its safety, according to the company’s SEC filing.

Clinical Benefit Blocks Mya Approval

The FDA sent Novocure a Not Approvable Letter — a rejection of its device-approval application. The proposed treatment covers adults with non-small cell lung cancer that has spread to the brain, following stereotactic radiation, a targeted form of radiation treatment.

Uncertainty about how much patients benefit from Optune Mya prevented approval, the company said in its regulatory update. Novocure said the FDA raised no concerns about the device’s safety profile.

Novocure is reviewing the agency’s feedback and plans to discuss whether a route to approval exists without additional clinical studies. Those discussions, and any later submissions, carry no guarantee of approval, the company said.

A Wearable Cancer-Treatment Business

Optune Mya’s application concerns a specific use of Novocure’s Tumor Treating Fields therapy, which delivers electric fields intended to kill cancer cells. The company’s other commercial products have approvals in certain countries for brain, pancreatic and lung cancers, as well as mesothelioma.

Its device lineup includes Optune Gio for glioblastoma, a brain cancer; Optune Lua for non-small cell lung cancer and pleural mesothelioma; and Optune Pax for pancreatic cancer. Most revenue comes from patients using Optune Gio in the U.S., Germany, France and Japan.

Novocure’s business depends on prescribed therapy: certified oncologists prescribe the devices, patients generally receive them directly, and the company charges insurers and other payers a monthly therapy fee. In some markets, including Japan, hospitals distribute the devices.

The company outsources manufacturing of device components. Its global sales team numbered 217 colleagues as of December 31, 2025, according to its annual report.

For Optune Mya, the next step Novocure plans is a discussion with the FDA about whether the clinical-benefit questions can be addressed without another round of studies.

Sources

More on Novocure

All Novocure (NVCR) coverage →